NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”),
a growing home health care organization, is pleased to announce the
release of financial results for the third quarter ended September
30, 2021.
All amounts are in United States dollars unless
otherwise specified.
Nova Leap Third Quarter of
2021
Highlights for the third quarter ended September
30, 2021 included the following:
-
Q3 2021 revenues were the highest in the Company’s history;
-
Q3 2021 was the Company’s fifth consecutive quarter of revenue
growth and third consecutive quarter of record revenues;
-
Q3 2021 revenues of $5,263,242 increased by 3.5% relative to Q2
2021 revenues of $5,085,445 and were 24.4% higher than Q3 2020
revenues of $4,231,326;
-
The Company had a cash balance of $6,320,266 as of September 30,
2021 as well as full access to the unutilized revolving credit
facility of $825,000;
- Nova Leap’s U.S. operating segment
qualified for the Employee Retention Credit (“ERC”) again in Q3
2021 and has recognized $1,846,969 in Other Income with a
corresponding receivable;
-
Q3 2021 Adjusted EBITDA of $59,100, which excludes government
assistance programs, was higher than Q2 2021 Adjusted EBITDA of
$42,974 and lower than Q3 2020 Adjusted EBITDA of $119,771 (See
reconciliation of Adjusted EBITDA to income (loss) from operating
activities in “Segmented Information” section in Q3 2021
MD&A);
-
Q3 2021 gross margin increased to 34.4% from Q2 2021 gross margin
of 34.0%;
-
The Company reported Net Income of $1,259,384 for Q3 2021 as
compared to Net Income of $467,773 for Q3 2020 and Net Income of
$345,470 for Q2 2021;
-
As a result of reported Net Income, Nova Leap exited Q3 2021 with
retained earnings for the first time in Company history. Q3 2021
retained earnings of $369,293 marks a substantial year over year
improvement from a Q3 2020 deficit of $2,117,750;
-
The Company reported an Adjusted Net Loss of ($305,638) for Q3 2021
as compared to an Adjusted Net Loss of ($82,913) for Q3 2020 and an
Adjusted Net Loss of ($242,804) for Q2 2021 (see reconciliation of
adjusted net (loss) income to net (loss) income in “Summary of
Quarterly Results” section in the Q3 2021 MD&A);
-
Subsequent to Q3, the Company announced the signing of definitive
agreements with home care companies located in the South Central
and Southeastern U.S. regions;
-
Subsequent to Q3, the Company received authorization to increase
it’s existing CAD$1 million revolving facility to CAD$1.5 million.
In addition, the Company secured a $1.6 million non-revolving
facility, from its Schedule 1 Bank, which may be used for
acquisition purposes should funds be required before ERC
receivables are collected; and
-
Subsequent to Q3, the Company received analyst coverage from
Echelon Partners.
President & CEO’s
Comments
Q3 Summary Comments
“As I reflect on our results for Q3, and as we
approach the midpoint of Q4, I believe we are well positioned for
accelerated growth.”, said Chris Dobbin, President & CEO of
Nova Leap. “I believe that the insider buying that occurred in Q3
is a positive signal to the Company’s investor base of the
confidence the Company’s insiders have in our business, as is the
growing interest in Nova Leap with additional analyst
coverage.”
We closed a small acquisition in Rhode Island
mid-quarter Q3 and another acquisition in Oklahoma with ten days
remaining in the quarter, both of which will have full period
results reflected in Q4. Further to these acquisitions, we
announced the signing of definitive agreements for acquisitions in
the South Central and Southeastern regions of the U.S., both of
which we anticipate closing in Q4.
While gross margins remain stable with a slight
increase over Q2, we reported a third consecutive quarter of record
revenues and fifth consecutive quarter of revenue growth. While
Adjusted EBITDA improved slightly from Q2, we recognize that there
remains a significant opportunity for improvement in financial
performance, particularly as it relates to the U.S. operating
segment. Access to the appropriate level of staffing remains a
challenge that we continue to address and expect to continue for
the foreseeable future. We continue to work hard in this area with
a view to eventually returning to pre-pandemic segment Adjusted
EBITDA margins.
With insider ownership at approximately 36%,
management executes with a long-term view in positioning the
Company for success. The staffing challenge described above also
creates opportunities for Nova Leap as home care owners look at
succession opportunities for their businesses.
Even with the acquisition announcements noted
above, Nova Leap has access to capital between a healthy cash
balance and the ERC. We remain active in evaluating additional
expansion opportunities and anticipate that Nova Leap will qualify
for approximately $2 million of ERC in Q4.
A Path Forward
As a company that started with the premise that
it could provide meaningful support to individuals living with
dementia and their families, we have been reluctant to provide any
forward-looking guidance as we prefer to let our results speak for
themselves and let investors react accordingly. However, as we move
through the pandemic, it is important for stakeholders to
understand the potential path forward that I believe is beginning
to take shape. As such, I offer the following comments with
underlying assumptions, all of which we believe are reasonable:
Target Financial Metrics
- The Company is targeting annualized
revenues by the end of Q1 2022 of at least $30 million;
- By the end of 2026, the Company is
targeting to achieve a minimum of $100 million in annualized
revenues combined with consolidated annualized Adjusted EBITDA of
at least $10 million.
Underlying Assumptions
- An average increase of $15 million
per year in annualized revenue by way of acquisitions over the
course of the next 5 years;
- Continued availability of industry
acquisition opportunities;
- Continued access to equity and debt
financing, as appropriate;
- Gross margin percentage in line
with historical range of 33-35% of revenues;
- Rebound of U.S. operating segment
Adjusted EBITDA to pre-pandemic levels;
- Reduction in head office costs as a
percentage of revenue through operating leverage consistent with
2016-2019 pre-pandemic trend; and
- Access to appropriate staffing
levels consistent with historical levels of acquired
operations.
Further information on the assumptions and risks
associated with our target financial metrics is included below
under the heading “Forward Looking Information”.
This news release should be read in conjunction
with the unaudited condensed interim consolidated financial
statements for the three and nine months ended September 30, 2021,
notes to the financial statements, and management's discussion and
analysis, which have been filed on SEDAR.
About Nova Leap
Nova Leap is an acquisitive home health care
services company operating in one of the fastest-growing industries
in the U.S. & Canada. The Company performs a vital role within
the continuum of care with an individual and family centered focus,
particularly those requiring dementia care. Nova Leap achieved the
#2 ranking on the 2020 Report on Business ranking of Canada’s Top
Growing Companies and the #10 Ranking in the 2019 TSX Venture 50™
in the Clean Technology & Life Sciences sector. The Company is
geographically diversified with operations in 7 different U.S.
states within the New England, South Central and Midwest regions as
well as Nova Scotia, Canada.
NON-IFRS MEASURES:
Gross margin is service revenues less cost of
service.
Adjusted Earnings before interest, taxes,
depreciation and amortization (“Adjusted EBITDA”), is calculated as
income (loss) from operating activities plus amortization and
depreciation and stock-based compensation expense.
Adjusted net income (loss) is net income (loss)
adjusted for stock-based compensation expense, acquisition
expenses, foreign exchange gains/losses, restructure charges, and
severance and other costs.
Annualized revenue and annualized EBITDA are
calculated as actual revenue or EBITDA extrapolated from the
beginning of the year or date of acquisition over 365 days.
FORWARD LOOKING
INFORMATION:
Certain information in this press release may
contain forward-looking statements, such as statements regarding
future expansions and cost savings, qualification for future ERC
amounts, timing of receipt of ERC, and plans regarding future
acquisitions and business growth, including the timing of closing
recently announced acquisitions, anticipated annualized revenue or
annualized recurring revenue run rate growth and anticipated
consolidated Adjusted EBITDA margins. This information is based on
current expectations and assumptions, including assumptions
described elsewhere in this release and those concerning general
economic and market conditions, availability of working capital
necessary for conducting Nova Leap’s operations, availability of
desirable acquisition targets and financing to fund such
acquisitions, and Nova Leap’s ability to integrate its acquired
businesses and maintain previously achieved service hour and
revenue levels, that are subject to significant risks and
uncertainties that are difficult to predict. Actual results might
differ materially from results suggested in any forward-looking
statements. Risks that could cause results to differ from those
stated in the forward-looking statements in this release include
the impact of the COVID-19 pandemic or any recurrence, including
government regulations or voluntary measures limiting the Company’s
ability to provide care to clients (such as shelter-in-place
orders, isolation or quarantine orders, distancing requirements, or
closures or restricted access procedures at facilities where
clients reside), increased costs associated with personal
protective equipment and sanitization supplies, staff and supply
shortages, regulatory changes affecting the home care industry or
government programs utilized by the Company (such as ERC), other
unexpected increases in operating costs and competition from other
service providers. All forward-looking statements, including any
financial outlook or future-oriented financial information,
contained in this press release are made as of the date of this
release and included for the purpose of providing information about
management's current expectations and plans relating to the future,
and these statements may not be appropriate for other purposes. The
Company assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking statements
unless and until required by securities laws applicable to the
Company. Additional information identifying risks and uncertainties
is contained in the Company's filings with the Canadian securities
regulators, which filings are available at www.sedar.com.
For further information:
Chris Dobbin, CPA, CADirector, President and CEONOVA
LEAP HEALTH CORP. T: 902 401 9480
E:cdobbin@novaleaphealth.com
CAUTIONARY STATEMENT:
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/ea4cb3ac-ab66-4cdc-b380-69bd8c91e714https://www.globenewswire.com/NewsRoom/AttachmentNg/eec12355-e331-40e2-954b-cb8f35b99587
Nova Leap Health (TSXV:NLH)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Nova Leap Health (TSXV:NLH)
Historical Stock Chart
Von Dez 2023 bis Dez 2024